Safety and Feasibility of Primary Closure Following Laparoscopic Common Bile Duct Exploration for Treatment of Choledocholithiasis.

BACKGROUND: T-tube drainage following laparoscopic common bile duct (CBD) exploration may lead to T-tube displacement and water-electrolyte disorders, affecting patients' quality of life. In particular, biliary peritonitis may develop in a small number of patients after T-tube removal, requiring reoperation. This prospective cohort study was performed to investigate the safety and feasibility of primary closure following laparoscopic CBD exploration for the treatment of choledocholithiasis. METHODS: Patients who were treated for choledocholithiasis by laparoscopic CBD exploration with primary closure from January 2019 to March 2022 comprised the PC group (n = 145). Patients who were treated for choledocholithiasis by laparoscopic CBD exploration with T-tube drainage during this period comprised the TD group (n = 153). Perioperative and follow-up outcomes were collected and statistically analyzed. RESULTS: The TD and PC groups showed significant differences in the operation time (124.6 ± 40.8 vs. 106 ± 36.4 min, P = 0.000) and postoperative hospital stay (7.1 ± 2.6 vs. 5.9 ± 2.0 days, P = 0.000). No significant difference was observed in terms of blood loss, the ratio of conversion to laparotomy, and postoperative parameters. Preoperative albumin and total bilirubin levels were the risk factors of bile leakage after surgery. No patients developed CBD stricture or carcinogenesis, The rates of residual and recurrent stones in the TD and PC groups were 1.97% vs. 1.40% and 1.31% vs. 1.40%, respectively, with no significant difference (P = 1.000 for both). CONCLUSIONS: Primary closure following laparoscopic CBD exploration is safe and feasible for selected patients with choledocholithiasis.

Laparoscopic versus open liver resection for hepatocellular carcinoma in posterosuperior segments.

BACKGROUND: Traditional open liver resection remains the classic procedure for hepatocellular carcinoma (HCC) located in the posterosuperior segments of the liver (segments I, IVa, VII, and VIII). This study compared the perioperative and oncologic results for laparoscopic versus open liver resection of HCC located in the posterosuperior segments, especially in patients with cirrhosis. METHODS: This study included 41 patients who underwent laparoscopic liver resection (LLR) and 86 who underwent open liver resection (OLR) for HCC in the posterosuperior segments between January 1, 2010, and December 31, 2012. There perioperative course and oncologic outcomes were retrospectively evaluated. RESULTS: There were no significant differences between the LLR and OLR groups in length of operation (242.41 ± 73.69 vs. 235.38 ± 65.80 min), transfusion rate (7.3 vs. 14.0 %), R0 resection rate (100 vs. 97.7 %), or tumor size (4.22 ± 2.05 vs. 4.30 ± 1.49 cm). In contrast, postoperative hospital stay (9.44 ± 2.72 vs. 14.53 ± 6.03 days) was significantly shorter, and postoperative complication rates (17.1 vs. 37.2 %) and intraoperative blood loss (272.20 ± 170.86 vs. 450.12 ± 344.70 mL) significantly lower in the LLR than in the OLR group. In addition, there was no significant difference between the two groups (LLR vs. OLR) regarding 1-year overall survival rate (95.1 vs. 89.5 %), 3-year overall survival rate (78 vs. 76.7 %,), 1-year disease-free survival rate (87.8 vs. 82.6 %,), and 3-year disease-free survival rate (70.7 vs. 68.6 %). CONCLUSIONS: LLR for selected patients with HCC in the posterosuperior segments may offer the same oncologic outcomes as conventional procedures, while being associated with such advantages as lower blood loss, fewer postoperative complications, and shorter hospital stay.

Safety and feasibility of laparoscopic hepatectomy for hepatocellular carcinoma in the posterosuperior liver segments.

BACKGROUND: Laparoscopic hepatectomy (LH) is mostly performed to treat solitary tumors in the anterolateral liver segments (II, III, IVb, V, and VI). Few reports are available on LH for the treatment of hepatocellular carcinoma (HCC) in the posterosuperior liver segments (I, IVa, VII, and VIII), especially in association with cirrhosis. The purpose of this study was to investigate the safety and feasibility of LH in this clinical setting. METHODS: From January 2008 to January 2011, LH was conducted in 56 patients with HCC in the posterosuperior liver segments (PS group) and 70 patients with HCC in the anterolateral liver segments (AL group) who were admitted to Southwest Hospital of the Third Military Medical University, Chongqing, China. The clinical data and follow-up results in the two groups of patients were retrospectively analyzed. RESULTS: No patient in either group died during the perioperative period. Statistically significant differences were found between the PS and AL groups in terms of the operation time (217.5 ± 63.7 vs 176.8 ± 48.4 min, P = 0.000), volume of blood loss (295.5 ± 186.8 vs 220.4 ± 164.2 ml, P = 0.001), conversion rate from laparoscopy to laparotomy (17.9 vs 7.1 %, P = 0.031), transfusion rate (16.1 vs 4.3 %, P = 0.025), cases of hepatic inflow occlusion (38/18 vs 28/42, P = 0.002), and duration of inflow occlusion (41.3 ± 16.3 vs 31.3 ± 12.2 min, P = 0.005). Parameters with no significant differences between the two groups of patients included tumor size (4.0 ± 1.5 vs 3.9 ± 1.7 cm, P = 0.894), resection margin (1.7 ± 0.7 vs 1.8 ± 0.6 cm, P = 0.102), postoperative complication rate (16.1 vs 17.1 %, P = 0.873), postoperative anal exhaust time (3.2 ± 0.6 vs 3.0 ± 0.6 days, P = 0.361), and postoperative hospital stay (10.5 ± 2.7 vs 10.0 ± 0.6 days, P = 0.102). The serum alanine transaminase (ALT) and aspartate aminotransferase (AST) levels on postoperative days 1 and 3 were significantly higher in the PS group than in the AL group. There were no significant differences in the postoperative levels of the serum total bilirubin, albumin, ALT, or AST levels on postoperative days 5 and 7. After 2-48 months of follow-up, no significant differences in the 1- and 3-year overall survival rates (92.9 vs 95.7 %, P = 0.487 and 76.0 vs 76.8 %, P = 0.878, respectively) or 1- and 3-year disease-free survival rates (85.7 vs 87.1 %, P = 0.797 and 57.6 vs 56.4 %, P = 0.806, respectively) were noted between the two groups. CONCLUSIONS: LH is safe and feasible for selected patients with HCC in the posterosuperior segments of the liver.